Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature (5)
Nature Medicine (3)
Nature Cancer (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (8)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Biophysics
Biotechnology
Cancer
Diseases
Genetics
Immunology
Medical research
Systems biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–9 of 9 results

Advanced filters: Author: Anton Dobrin Clear advanced filters

Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies

Dobrin et al. develop a fusion receptor comprising the CD80 ectodomain and the 4-1BB cytoplasmic domain, which engages the CD28 and 4-1BB pathways and increases the antitumor potency of HLA-independent (HIT) and TCR-engineered T cells.

Anton Dobrin
Pieter L. Lindenbergh
Mohamad Hamieh
Research19 Mar 2024
Nature Cancer

Volume: 5, P: 760-773
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell activity that may correlate with delayed recurrence of disease.

Luis A. Rojas
Zachary Sethna
Vinod P. Balachandran
ResearchOpen Access10 May 2023
Nature

Volume: 618, P: 144-150
Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Judith Feucht
Jie Sun
Michel Sadelain
Amendments and Corrections28 Jan 2019
Nature Medicine

Volume: 25, P: 530
HIV immune evasin Nef enhances allogeneic CAR T cell potency

HIV-1 immune evasin Nef reduces activation-induced cell death and promotes survival of chimeric antigen receptor (CAR) T cells; thus, virus-like immune escape enhances therapeutic efficacy of allogeneic CAR T cells.

Karlo Perica
Ivan S. Kotchetkov
Michel Sadelain
Research30 Jan 2025
Nature

Volume: 640, P: 793-801
TET2 guards against unchecked BATF3-induced CAR T cell expansion

Disruption of TET2 increases the antitumour efficacy of CAR T cells, but establishes an epigenetic state that is prone to hyperproliferation and accumulation of secondary mutations.

Nayan Jain
Zeguo Zhao
Michel Sadelain
Research08 Feb 2023
Nature

Volume: 615, P: 315-322
HLA-independent T cell receptors for targeting tumors with low antigen density

HLA-independent T cell receptors, in which the heavy and light chains of a chimeric antigen receptor are incorporated into the endogenous T cell receptor locus, are more effective than CD28-based chimeric antigen receptors at targeting tumors with low antigen expression.

Jorge Mansilla-Soto
Justin Eyquem
Michel Sadelain
Research13 Jan 2022
Nature Medicine

Volume: 28, P: 345-352
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

The human immune system naturally edits cancers of high-quality neoantigens.

Marta Łuksza
Zachary M. Sethna
Vinod P. Balachandran
ResearchOpen Access19 May 2022
Nature

Volume: 606, P: 389-395
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Chimeric antigen receptors (CARs) promote antigen loss in tumour cells by trogocytosis, which results in T cell fratricide killing and exhaustion but can be counteracted by cooperative killing and combinatorial targeting.

Mohamad Hamieh
Anton Dobrin
Michel Sadelain
Research27 Mar 2019
Nature

Volume: 568, P: 112-116
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

A novel chimeric antigen receptor (CAR) T cell design improves therapeutic efficacy by balancing effector and memory profiles.

Judith Feucht
Jie Sun
Michel Sadelain
Research17 Dec 2018
Nature Medicine

Volume: 25, P: 82-88